No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 74.5x · 10Y median 93.3x · 14th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 11
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:23:25.426Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Rapport Therapeutics, Inc. Common Stock (RAPP) stock was $31.15 as of Oct 6, 2026, 4:00 PM EDT, down 3.23% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +12.7%
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders.
Biotechnology · Boston, MA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-1.21
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.19
vs Estimate
$-0.99
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1RAPP | $1.49B | $31.15 | -3.23% | +12.72% | N/A | N/A | N/A |
| 2PAHC | $1.48B | $36.61 | -1.56% | -1.78% | +14.40% | +5.27% | vs RAPP |
| 3ETON | $1.50B | $54.77 | -1.53% | +177.71% | +63.04% | N/A | vs RAPP |
| 4NUTX | $1.50B | $218.40 | -2.93% | +107.84% | -18.99% | -27.99% | vs RAPP |
| 5GHRS | $1.48B | $21.52 | -2.93% | +68.81% | +0.52% | N/A | vs RAPP |
| 6MAZE | $1.46B | $26.43 | +0.00% | -2.50% | N/A | N/A | vs RAPP |
forward FY estimate
N/A
$0.00
vs Estimate
$2.22M
Consensus Rating
Based on 12 analysts
Average Price Target
$62.88
+101.9% upside
Low
$50.00
Current
$31.15
High
$80.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.36 | $-1.21 | $-1.02 | 7 |
| Quarter ending Dec 2026 | $-1.54 | $-1.21 | $-1.02 | 7 |
| Quarter ending Mar 2027 | $-1.30 | $-1.30 | $-1.30 | 2 |
| Quarter ending Jun 2027 | $-1.33 | $-1.33 | $-1.33 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-4.46 | $-4.04 | $-3.62 | 9 |
| FY 2027 | $-6.72 | $-4.86 | $-3.23 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $20.00M | $20.00M | $20.00M | 10 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
